(Reuters) – The U.S. Centers for Disease Control and Prevention is urging people at high risk of mpox to get two doses of Bavarian Nordic’s Jynneos vaccine, based on new evidence from a U.S. study showing that two doses were more effective at preventing infection than one, officials said on Thursday.
The study, published on Thursday, offered some of the first evidence on the efficacy of the Jynneos vaccine, which was deployed last year during a global outbreak of mpox that affected more than 30,000 people in the United States.
(Reporting by Leroy Leo in Bengaluru; Editing by Julie Steenhuysen and Bill Berkrot)